Get started
Author

Erica J. Caveney

Observed names: E. Caveney, Erica Caveney
OpenAlex ID: A5000355875
Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
2015 · Friedrich Mittermayer, Erica Caveney, et al. · Current Diabetes Reviews · 48
PDF
Diabetes and Biomarkers
2011 · Erica J. Caveney, Oren J. Cohen · Journal of Diabetes Science and Technology · 36
PDF
Protein inhibitor of activated STAT3 inhibits adipogenic gene expression
2005 · Jianbei Deng, Kunjie Hua, et al. · Biochemical and Biophysical Research Communications · 34
Pharmaceutical interventions for obesity: a public health perspective
2010 · E. Caveney, B. J. Caveney, et al. · Diabetes Obesity and Metabolism · 29
Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
2016 · Friedrich Mittermayer, Erica Caveney, et al. · Current Diabetes Reviews · 19
With regard to the paper by Zannad et al. entitled Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment versus risk aversion
2016 · J. Rick Turner, Dilip R. Karnad, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 5
PDF
With regard to the papers by Kumaret al.and de Leeuw and de Boer addressing the cardiovascular safety and efficacy of anti-diabetic drugs
2016 · J. Rick Turner, Erica Caveney, et al. · European Heart Journal - Cardiovascular Pharmacotherapy · 3
PDF
Response to the ‘Comment on the editorial by Turner et al. on Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.’
2017 · J Turner Rick, Erica Caveney · European Heart Journal - Cardiovascular Pharmacotherapy · 1
Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. A Review of FDA Guidance
2010 · Erica Caveney, J. Rick Turner · 1
Works count: 9
Citation count: 176
H-index: 5
I10-index: 5
Year
Topic
Type